Published in Cancer Weekly, October 6th, 1997
The goal of these studies is to develop an effective immunotherapeutic response against prostate and breast cancers. Cel-Sci's L.E.A.P.S. technology has been scheduled for testing with the SV40 T-antigen peptides using the C3(1)/Tag transgenic mouse model...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.